@article{ccb233a6c0674c0ba92ede25c9473734,
title = "Adverse events over two years after retropubic or transobturator midurethral sling surgery: Findings from the Trial of Midurethral Slings (TOMUS) study",
abstract = "Objective: To describe surgical complications in 597 women over a 24-month period after randomization to retropubic or transobturator midurethral slings. Study Design: During the Trial of Midurethral Slings study, the Data Safety Monitoring Board regularly reviewed summary reports of all adverse events using the Dindo Surgical Complication Scale. Logistic regression models were created to explore associations between clinicodemographic factors and surgical complications. Results: A total of 383 adverse events were observed among 253 of the 597 women (42%). Seventy-five adverse events (20%) were classified as serious (serious adverse events); occurring in 70 women. Intraoperative bladder perforation (15 events) occurred exclusively in the retropubic group. Neurologic adverse events were more common in the transobturator group than in retropubic (32 events vs 20 events, respectively). Twenty-three (4%) women experienced mesh complications, including delayed presentations, in both groups. Conclusion: Adverse events vary by procedure, but are common after midurethral sling. Most events resolve without significant sequelae.",
keywords = "adverse events, midurethral slings, surgical complications",
author = "Linda Brubaker and Norton, {Peggy A.} and Albo, {Michael E.} and Chai, {Toby C.} and Dandreo, {Kimberly J.} and Lloyd, {Keith L.} and Lowder, {Jerry L.} and Sirls, {Larry T.} and Lemack, {Gary E.} and Arisco, {Amy M.} and Yan Xu and Kusek, {John W.}",
note = "Funding Information: This research was funded, in part, by National Institutes of Health (NIH) grants to P.A.N., M.E.A., and L.T.S. M.E.A. receives financial support for travel, review activities, and manuscript review as well as administrative support from the NIH and is a consultant to Allergan. Grants were provided by Allergen (T.C.C., K.L.L., and G.E.L.), Contura (G.E.L.), and the New England Research Institute (Y.X.). T.C.C. serves as a consultant to Pfizer, Astellas, and Medtronic; K.L.L., to Astellas and Watson; and G.E.L., to Pfizer, Astellas, and Pneumoflex. L.T.S. receives travel support from the NIH. L.B., K.J.D., J.L.L., A.M.A., and J.W.K. report no conflict of interest. Funding Information: Supported by cooperative agreements from the National Institute of Diabetes and Digestive and Kidney Diseases , U01 DK58225 , U01 DK58229 , U01 DK58234 , U01 DK58231 , U01 DK60379 , U01 DK60380 , U01 DK60393 , U01 DK60395 , U01 DK60397 , and 60401 . Support was also provided by the National Institute of Child Health and Human Development and Office of Research in Women's Health, NIH. ",
year = "2011",
month = nov,
day = "1",
doi = "10.1016/j.ajog.2011.07.011",
language = "English",
volume = "205",
pages = "498.e1--498.e6",
journal = "American journal of obstetrics and gynecology",
issn = "0002-9378",
number = "5",
}